AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A platelet aggregation inhibitor comprising a quinolone derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient:



(I)

[the symbols in the formula have the following meanings:

X: C-R^7 or N;

Y: C-R^6 or N;

R^{11}: ~~-H, a lower alkyl which may be substituted, or an amino which may be substituted with a lower alkyl which may be substituted~~;

R^{12}: ~~-H, or~~ a lower alkyl ~~or an aryl~~ which ~~respectively may be~~is substituted~~, provided that R^{11} and R^{12} together with the adjacent nitrogen may form a cyclic amino which may be substituted~~;

R^2: a lower alkyl or, a cycloalkyl~~, an aryl or a hetero ring, which respectively may be substituted~~;

R^3: a halogen~~, a lower alkyl or -O-lower alkyl~~;

R^4: a cycloalkyl ~~or a non-aromatic hetero ring, which respectively may be substituted, or a lower alkyl substituted with a cycloalkyl, provided that when R4 represents a non-aromatic hetero ring which may be substituted, a carbon atom constituting the ring binds to the adjacent NH~~;

R^5: ~~-H, a halogen, cyano, nitro, a lower alkyl, a halogeno-lower alkyl, a cycloalkyl, an aryl, a hetero ring, -O-lower alkyl, -OH, -NHCO-lower alkyl, -N(lower alkyl)CO-lower alkyl, an amino which may be substituted with a lower alkyl, or a cyclic amino which may be substituted~~;

R^6: ~~-H, a halogen, a lower alkyl or a halogeno-lower alkyl;~~

R^7: ~~-H, a halogen, a lower alkyl or a halogeno-(lower alkyl);~~

~~provided that when Y represents C-R^6, R^2 and R^6 together may form a lower alkylene or a lower alkenylene~~.

2. (original): A P2Y12 inhibitor comprising the compound according to claim 1 as an active ingredient.

3. (withdrawn): A method for inhibiting platelet aggregation in an individual, comprising administering a therapeutically effective amount of the compound of claim 1, and at least one pharmaceutically acceptable carrier, to the individual.

4. (withdrawn): A method for inhibiting P2Y12 in an individual, comprising administering a therapeutically effective amount of the compound of claim 1, and at least one pharmaceutically acceptable carrier, to the individual.

5 - 6. (canceled).

7. (currently amended): A quinolone derivative represented by the formula (I-a) or a pharmaceutically acceptable salt thereof:



(I-a)

[the symbols in the formula have the following meanings:

X: C-R^7 or N;

Y: C-R^6 or N;

~~R^{11}: -H, a lower alkyl which may be substituted, or an amino which may be substituted with a lower alkyl which may be substituted;~~

R^{12}: ~~-H, or~~ a lower alkyl ~~or an aryl~~, which ~~respectively may be~~is substituted~~, provided that R^{11} and R^{12} together with the adjacent nitrogen may form a cyclic amino which may be substituted~~;

R^2: a lower alkyl~~,~~ or a cycloalkyl~~, an aryl or a hetero ring, which respectively may be substituted~~;

R^3: a halogen~~, a lower alkyl or -O-lower alkyl~~;

R^4: a cycloalkyl ~~or a non-aromatic hetero ring, which respectively may be substituted, or a lower alkyl substituted with a cycloalkyl; provided that wherein R^4 represents a non-aromatic hetero ring which may be substituted, a carbon atom constituting the ring binds to the adjacent NH~~;

~~R^5: -H, a halogen, cyano, nitro, a lower alkyl, a halogeno-lower alkyl, a cycloalkyl, an aryl, a hetero ring, -O-lower alkyl, -OH, -NHCO-lower alkyl, -N(lower alkyl)CO-lower alkyl, an amino which may be substituted with a lower alkyl, or a cyclic amino which may be substituted~~;

~~R^6: -H, a halogen, a lower alkyl or a halogeno-lower alkyl~~;

~~R^7: -H, a halogen, a lower alkyl or a halogeno-(lower alkyl);~~

~~provided that when Y represents C-R^6, R^2 and R^6 together may form a lower alkylene or a lower alkenylene and provided that 7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbohydrazide is excluded~~.

8. (original): The compound according to claim 7, wherein X is CH.

9.-11. (canceled).

12. (currently amended): The compound according to ~~claim 11~~claim 8, wherein R^{12} is a lower alkyl substituted with one or more substituent groups selected from Group Q, wherein at least one of the substituent groups is selected from Group P:

Group P: $-CO_2H$, $-SO_3H$, $-P(O)(OH)_2$, and $-OP(O)(OH)_2$; and

Group Q: -F, -OH, $-CO_2H$, $-SO_3H$, $-P(O)(OH)_2$, and $-OP(O)(OH)_2$

13. (canceled).

14. (currently amended): The compound according to claim 7, which is

~~[2-({[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)ethyl]phosphonic acid,~~

(2S)-2-({[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)butanedioic acid,

~~2-({[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)ethyl dihydrogen phosphate,~~

(2S)-2-({[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)pentanedioic acid,

~~{2-[({7-(cyclohexylamino)-6-fluoro-4-oxo-1-[(3S)-tetrahydrofuran-3-yl]-1,4-dihydroquinolin-3-yl}carbonyl)amino]ethyl}phosphonic acid,~~

~~{2-[({7-(cyclohexylamino)-6-fluoro-4-oxo-1-[(3R)-tetrahydrofuran-3-yl]-1,4-dihydroquinolin-3-yl}carbonyl)amino]-ethyl}phosphonic acid,~~

~~[2-({[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)-1,1-difluoroethyl]phosphonic acid,~~

~~{2-[({7-(cyclohexylamino)-6-fluoro-1-[2-hydroxy-1-(hydroxymethyl)ethyl]-4-oxo-1,4dihydroquinolin-3-yl}carbonyl)amino)ethyl}phosphonic acid,~~

~~[2-({[7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydrocinnolin-3-yl]carbonyl}amino)ethyl]phosphonic acid,~~

~~[2-({[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydrocinnolin-3-yl]carbonyl}amino)ethyl]phosphonic acid,~~

~~[2-({[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)ethyl]phosphonic acid,~~

(2S)-2-({[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)pentanedioic acid or,

(2S)-2-({[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydrocinnolin-3-yl]carbonyl}amino)pentanedioic acid ~~or~~

~~[2-({[7-(cyclohexylamino)-1-(2,2-dimethyl-1,3-dioxan-5-yl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)ethyl]phosphonic acid~~, or a pharmaceutically acceptable salt thereof.

15. (currently amended): A pharmaceutical composition comprising a compound according to any one of claims 7, 8, 12 or ~~through~~ 14 and a pharmaceutically acceptable carrier.

16. (original): The pharmaceutical composition according to claim 15, which is a platelet aggregation inhibitor.

17. (original): The pharmaceutical composition according to claim 15, which is a P2Y12 inhibitor.

18. (withdrawn - currently amended): A method for inhibiting platelet aggregation in an individual, comprising administering a therapeutically effective amount of the compound of any one of claims 7, 8, 12 or ~~through~~ 14, and at least one pharmaceutically acceptable carrier, to the individual.

19. (withdrawn - currently amended): A method for inhibiting P2Y12 in an individual, comprising administering a therapeutically effective amount of the compound of any one of claims 7, 8, 12 or ~~through~~ 14, and at least one pharmaceutically acceptable carrier, to the individual.

20 - 21. (canceled).

22. (new): The compound according to claim 7, which is [2-({ [7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1 ,4-dihydroquinolin-3-yl]carbonyl} amino)ethyl]phosphonic acid,

2-({[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)ethyl dihydrogen phosphate,

[2-({[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)-1,1-difluoroethyl]phosphonic acid,

[2-({[7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydrocinnolin-3-yl]carbonyl}amino)ethyl]phosphonic acid,

[2-({ [7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-l ,4-dihydrocinnolin-3-yl]carbonyl}amino)ethyl]phosphonic acid, or

[2-({ [7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)ethyl]phosphonic acid,

or a pharmaceutically acceptable salt thereof.